Jump to main content
Jump to site search

Issue 42, 2020
Previous Article Next Article

Single-domain antibody C7b for address delivery of nanoparticles to HER2-positive cancers

Author affiliations

Abstract

Monoclonal antibodies (mAb) demonstrate great potential as immunotherapy agents for the treatment of diseases such as cancer as well as tagging for the targeted delivery of multicomponent therapeutic or diagnostic systems. Nevertheless, the large physical size, poor stability of mAbs and abnormal allergic reactions still remain the main issues affecting their generalised use. Single-domain antibodies (sdAb) are seen as the next generation of antibody derived therapeutics and diagnostics. This work presents the optimised production method for HER2-specific sdAb C7b, which led to an ∼11-fold increase in protein yield. In addition, the in vitro and in vivo efficiencies of the targeted delivery of a model nanoparticle cargo (50 nm silica particles doped with Mo6 phosphorescent clusters) conjugated to C7b against those conjugated to HER2-specific trastuzumab is benchmarked. Specifically, this paper demonstrates the significantly higher rate of accumulation in and excretion from xenograft cancer tissue of nanoparticles with C7b, which is of particular importance for diagnostics, i.e. delivery of imaging agents.

Graphical abstract: Single-domain antibody C7b for address delivery of nanoparticles to HER2-positive cancers

Back to tab navigation

Supplementary files

Article information


Submitted
30 Jun 2020
Accepted
29 Sep 2020
First published
30 Sep 2020

Nanoscale, 2020,12, 21885-21894
Article type
Paper

Single-domain antibody C7b for address delivery of nanoparticles to HER2-positive cancers

Y. A. Vorotnikov, E. D. Novikova, A. O. Solovieva, D. V. Shanshin, A. R. Tsygankova, D. N. Shcherbakov, O. A. Efremova and M. A. Shestopalov, Nanoscale, 2020, 12, 21885
DOI: 10.1039/D0NR04899B

Social activity

Search articles by author

Spotlight

Advertisements